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Abstract
Background: Meesmann epithelial corneal dystrophy (MECD) is an inherited eye disorder caused by dominant-negative
mutations in either keratins K3 or K12, leading to mechanical fragility of the anterior corneal epithelium, the outermost
covering of the eye. Typically, patients suffer from lifelong irritation of the eye and/or photophobia but rarely lose visual
acuity; however, some individuals are severely affected, with corneal scarring requiring transplant surgery. At present no
treatment exists which addresses the underlying pathology of corneal dystrophy. The aim of this study was to design and
assess the efficacy and potency of an allele-specific siRNA approach as a future treatment for MECD.
Methods and Findings: We studied a family with a consistently severe phenotype where all affected persons were shown
to carry heterozygous missense mutation Leu132Pro in the KRT12 gene. Using a cell-culture assay of keratin filament
formation, mutation Leu132Pro was shown to be significantly more disruptive than the most common mutation, Arg135Thr,
which is associated with typical, mild MECD. A siRNA sequence walk identified a number of potent inhibitors for the mutant
allele, which had no appreciable effect on wild-type K12. The most specific and potent inhibitors were shown to completely
block mutant K12 protein expression with negligible effect on wild-type K12 or other closely related keratins. Cells
transfected with wild-type K12-EGFP construct show a predominantly normal keratin filament formation with only 5%
aggregate formation, while transfection with mutant K12-EGFP construct resulted in a significantly higher percentage of
keratin aggregates (41.75%; p,0.001 with 95% confidence limits). The lead siRNA inhibitor significantly rescued the ability
to form keratin filaments (74.75% of the cells contained normal keratin filaments; p,0.001 with 95% confidence limits).
Conclusions: This study demonstrates that it is feasible to design highly potent siRNA against mutant alleles with single-
nucleotide specificity for future treatment of MECD.
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Introduction
Meesmann epithelial corneal dystrophy (MECD) is a hereditary
eye disorder that is inherited in an autosomal dominant manner
[1,2]. Previously, we demonstrated that the molecular basis of
MECD is a dominant-negative mutation in either of the KRT3 or
KRT12 genes encoding keratins K3 or K12, respectively, which
are expressed only in the keratinocyte cells of the anterior corneal
epithelium [3]. The K3/K12 intermediate filament cytoskeleton
imparts mechanical strength to these keratinocytes and therefore,
dysfunction of this system leads to mechanical fragility of the
anterior corneal epithelium. Since then, more than 20 distinct
disease-causing mutations have been reported in K3 and K12 in
MECD families; see intermediate filament mutation database,
http://www.interfil.org/ [4]. The vast majority of MECD
mutations, like that of all the other keratin disorders, are point
mutations leading to amino acid substitutions within the keratin
rod domain. Such mutations are known to be highly detrimental
to keratin function through a dominant-negative pathomechanism
[5].
MECD can cause foreign body sensation and photophobia but
is often asymptomatic and detected in the course of routine eye
examination. Slit lamp observation shows multitudinous micro-
cysts within the anterior epithelium, evident even in symptomless
individuals. A subtle feature is the presence of gray serpiginous
lines within the anterior epithelium. Rarely, a more severe
phenotype with corneal erosions and scarring can lead to
significant loss of visual acuity requiring treatment by keratoplasty
or corneal grafting [6,7,8]. To date no molecular mechanism has
emerged for the greater clinical severity observed in some families.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28582Similarly, no therapy has been developed which addresses the
underlying pathology associated with any of the corneal
dystrophies.
In recent years, RNA interference (RNAi) has been identified as
a highly potent and specific means of silencing genes in a user-
defined manner. This process of sequence specific, post-transcrip-
tional inhibition of gene expression has great potential to be
developed as a novel therapeutic approach for a number of
disorders where gene inhibition is predicted to be therapeutic [9].
As a dominant-negative disease, MECD represents an ideal model
for RNAi therapy development aimed at specific ablation of the
mutant allele. In particular, the small size, transparency and
accessibility of the anterior corneal epithelium combine to make
this tissue ideal for siRNA delivery via topical formulations. In
addition, the microcysts that are the hallmark of the disease
process can be readily imaged in a non-invasive manner to
monitor efficacy in vivo. Although siRNA therapy of this type
requires design of allele-specific silencing reagents for each
individual mutation [10,11], most MECD patients in Europe
have a common founder mutation Arg135Thr [3,12].
Here we assessed an extended family with MECD where the
clinical presentation was consistently severe. Molecular genetic
analysis, coupled with protein expression studies in cultured cells,
pointed to a molecular mechanism for the unusually severe
phenotype in the kindred. We used a K12-luciferase reporter gene
assay to systematically perform a sequence walk across the point
mutation in order to identify siRNAs that potently and specifically
inactivated the mutant allele without any gene silencing effect on
the normal allele. We also confirmed findings at a protein level
and in a cell-based model system, where lead inhibitors
significantly reversed the cytoskeletal aggregation phenotype.
Overall this therapeutic approach shows promise, and coupled
with a suitable delivery system for the ocular surface, such reagents
have huge potential for treatment of MECD, with the added
potential of designing similar siRNAs for dominant-negative
mutations in many other corneal dystrophies via a personalized
medicine approach.
Results
An extended British multigenerational family (MECD Family 1)
was studied showing autosomal dominant inheritance of MECD
(Fig. S1). All members of the kindred exhibited an unusually severe
clinical presentation (Fig. 1). Specifically, affected persons tended
to have recurrent corneal erosions with scarring leading to pain
and reduced visual acuity. Slit lamp photography revealed not
only multiple microcysts in the anterior epithelium but also uneven
corneal topography secondary to damage and scarring of the
underlying basement membrane and anterior stroma (Fig. 1A–C).
A number of individuals in the family had been treated with
corneal grafting, which is uncommon in MECD.
Hot spot mutation regions exons 1 and 7 of the KRT3 gene,
encoding protein K3, and exons 1 and 6 of the KRT12 gene,
encoding K12, were screened for mutations by direct DNA
sequencing of specific PCR products. This revealed a novel
heterozygous transition mutation in the proband and all affected
members of Family 1, c.395T.C in exon 1 of the KRT12 gene
(Fig. 2A&B). This mutation predicts the amino acid change leucine
to proline at codon 132 (Leu132Pro). This mutation is located in
the functionally critical helix initiation motif at the start of the
helix 1A domain of the K12 polypeptide. The mutation destroys a
recognition site for the restriction enzyme Mse I, which allowed
rapid exclusion of this sequence change from 50 normal, unrelated
and ethnically matched control individuals by Mse I digestion of
KRT12 exon 1 PCR fragments as demonstrated in Fig. 2C. The
c.395T.C mutation was also confirmed by PCR and DNA
sequencing using a different primer set.
The most common K12 mutation in Europeans associated with
typical, mild MECD is Arg135Thr [3,12]. To investigate why
mutation Leu132Pro produced a more severe phenotype, both
untagged and EGFP-tagged cDNA expression constructs were
generated for wild-type human K3 and K12 to allow visualization
of keratin filament or aggregate formation in transfected cells.
Similarly, the expression constructs for the K12 mutants
Leu132Pro and Arg135Thr were generated by site-directed
mutagenesis. Initial attempts to express wild-type K12 by transient
transfection into the simple epithelial cell line PtK2 [13], a
standard assay of keratin filament function [14,15], did not result
in filamentous keratin staining but instead, dense aggregates were
seen over a range of time points (not shown). PtK2 cells are used to
assay keratin filament assembly because flat morphology and the
presence of few endogenous keratins allow clear visualization of
the cytoskeleton, compared to corneal or epidermal keratinocytes
[15,16]. This observation that transient expression of wild-type
K12 did not result in filament formation suggested that type I
keratin K12 is unable to form polymers with the endogenous
keratins within PtK2 cells, namely K7, K8, K18 and K19 [16],
and probably requires the presence of its natural type II keratin
polymerization partner, K3. In contrast, other type I keratins, such
Figure 1. Clinical characteristics of MECD. (A) Ophthalmic
examination of the proband from one of the families showed grey
lines in the corneal epithelium, one of the characteristics of MECD. Slit
lamp photography revealed multiple microcysts in the anterior
epithelium (B) and uneven corneal topography secondary to damage
and scarring of the underlying basement membrane (C).
doi:10.1371/journal.pone.0028582.g001
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[14,15]. Subsequent co-transfection of both wild-type K3 and K12
constructs resulted in production of a well-developed intermediate
filament network by 24–48 hours post-transfection (Fig. 3A). Co-
transfection of mutant versions of K12, Leu132Pro or Arg135Thr,
with wild-type K3, resulted in a high percentage of K3/K12-
positive cells containing dense cytoplasmic aggregates of K3/K12
protein (Fig. 3B). Over-expression of wild-type keratins produces
aggregates within the first 12 hours of transfection, however, these
largely integrate into filament networks by 24–48 hours and persist
in filamentous form at later time points [14,15]. In contrast,
dominant-negative mutant keratins produce aggregates that persist
in a large percentage of cells at 24–48 hours post-transfection. By
this means, a measure of the pathogenicity of particular mutations
can be gained by measuring the percentage transfected cells
showing filaments versus aggregates observed at, for example, 24
or 48 hours post-transfection [14,15]. Thus, the percentage of cells
showing filamentous K3/K12 staining at 48 hours was deter-
mined for wild-type, Leu132Pro and Arg135Thr versions of K12,
co-transfected with K3 into PtK2 cells (Fig. 3C). Expression of K3
along with either of the K12 mutants resulted in a much lower
percentage of filamentous keratin than K3 along with wild-type
K12 and the difference was highly statistically significant for both
Leu132Pro and Arg135Thr compared to wild-type (p,0.001).
Importantly, Leu132Pro produced a consistently lower percentage
of filamentous keratin than Arg135Thr (p,0.05; Fig. 3C), i.e. in
this assay Leu132Pro is more disruptive to keratin function than
Arg135Thr.
In order to develop a therapeutic starting point for MECD, a
sequence walk was performed with all 19 possible siRNA
inhibitors designed to be specific for the K12 Leu132Pro point
mutation as demonstrated in Table S1. For each inhibitor
investigated, the effect on K12-firefly luciferase reporter gene
expression was determined in four replicate experiments over a
range of siRNA molar concentrations (0, 0.01, 0.05, 0.25, 1.25 and
6.25 nM) against the wild-type and Leu132Pro mutant K12-firefly
luciferase constructs. In each case, the data was normalized against
co-transfected Renilla luciferase as a control for cell viability and
transfection efficiency. Representative results are presented
graphically in Fig. 4. A non-specific siRNA (NSC4) negative
control had no inhibitory effect on either the wild-type K12
reporter or the Leu132Pro reporter, as predicted, while a known
potent siRNA against firefly luciferase (siLuc), used as a positive
control, knocked down the expression of both wild-type and
mutant constructs roughly equally and over a wide range of siRNA
concentrations (Fig. 4).
Figure 2. Molecular genetic analysis of K12 for the MECD
families. (A) Sequence excerpt from K12 exon 1 derived from a normal
person. (B) A novel heterozygous transition mutation was found in the
proband: c.395T.C in exon 1 of the KRT12 gene predicting a leucine to
proline amino acid substitution at codon 132 (designated p.Leu132Pro,
or for brevity, Leu132Pro). (C) The mutation destroys a recognition site
for the restriction enzyme Mse I site, which allowed rapid exclusion of
this sequence change from 50 normal, unrelated and ethnically
matched control individuals by Mse I digestion of KRT12 exon 1 PCR
fragments. Nor=unaffected members of Family I; Aff=affected persons
from Family 1. White arrowhead=filamentous keratin; blue arro-
whead=keratin aggregates.
doi:10.1371/journal.pone.0028582.g002
Figure 3. Aggregate formation in cells transfected with mutant
keratins. (A) Co-transfection of both untagged wild-type K3 and K12
cDNA constructs into Ptk2 cells resulted in production of a well-
developed intermediate filament network by 24–48 hours post-
transfection as demonstrated by immunofluorescence staining (anti-
body AE5 against K3). (B) Co-transfection of mutant versions of K12,
Leu132Pro or Arg135Thr, with wild-type K3, resulted in a high
percentage of K3/K12-positive cells containing dense cytoplasmic
aggregates of K3/K12 protein demonstrated by the red foci. Original
magnification 606. Scale bar=10 mm. (C) The percentage of filamen-
tous versus aggregative-containing cells was scored from 100 cells
transiently transfected with wild-type or mutant forms of K12, at
24 hours post-transfection. Error bars represent standard error of the
mean of replicate experiments. Wild-type K12 showed close to 100%
filamentous keratin while both mutations showed a significant
difference in the percentage of cells containing aggregates, when
compared to wild-type (p,0.001). The common MECD mutation
Arg135Thr showed significantly less aggregate formation compared
to the Leu132Pro mutant (p,0.05).
doi:10.1371/journal.pone.0028582.g003
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wild-type and Leu132Pro mutant K12 equally, over a range of
concentrations, such as K12-L132P-1, or K12-L132P-7 and
therefore did not discriminate wild-type and mutant alleles. Some
test inhibitors had little or no effect on expression of either the
wild-type or mutant reporter gene expression, even at high
concentrations, such as K12-L132P-13 or K12-L132P-16. How-
ever, from the 19 inhibitors, a number were able to specifically and
potently inhibit the mutant allele with little or no effect on the
wild-type allele, such as K12-L132P-4, 5, 9, 10, 11, 12, 14 and 15.
Although all of these have good potential for therapeutic use,
arguably the best inhibitor for further development was K12-
L132P-9, where expression of the wild-type allele is not
significantly knocked down, even at the highest concentrations,
whereas the Leu132Pro mutant allele is potently knocked down
even at the lowest siRNA concentration of 0.01 nM (Fig. 4).
To confirm the discriminative down-regulation effect of those
siRNAs identified above, AD293 cells were transfected with wild-
type or mutant K12-EGFP constructs and three representative
discriminatory siRNAs K12-L132P-9, 14 and 15 at a final
concentration of 5 nM. AD293 cells were used because they lack
endogenous K3 or K12 expression and exhibit a high transfection
efficiency. Non-specific siRNA NSC4 was used as a negative
control and distilled water was used as an ‘‘untreated’’ control.
Fluorescent imaging at 48 hours post-transfection showed that the
expression of both wild type and mutant K12-EGFP constructs
was almost equal for cells treated with negative control siRNA
NSC4 (Fig. 5A). On the contrary, there was a significant reduction
of fluorescence in the cells transfected with mutant K12-EGFP
and inhibitors (Fig. 5A).
To confirm and quantify the highly differential inhibitory effect
of the lead inhibitor K12-L132P-9 on mutant K12, western blot
analysis was performed. Cells were transfected as described above
with the expression of wild type and mutant K12-EGFP constructs
similar in both untreated and NSC4 treated cells (equal loading
was confirmed). In contrast, when the cells were treated with
siRNA K12-L132P-9, mutant K12 protein expression was almost
completely knocked out, although the expression of wild type K12
construct treated with the same siRNA showed a negligible
reduction, comparable to the non-specific control NSC4 treatment
(Fig. 5B). These data confirm that siRNA K12-L132P-9 is highly
potent and highly specific for the K12 mutation Leu132Pro at the
level of protein expression. The lead inhibitor (K12-L132P-9) was
investigated for off-target effects on other keratins in HaCaT cells
[17], which endogenously express a range of keratins, including
K14, which is closely related to K12 in terms of sequence
conservation. Coomassie blue stained gels showed no reduction on
any keratins expressed in this keratinocyte cell line (Fig. 6). In
contrast, a positive control siRNA against K6a [18], strongly
knocked down K6a protein expression at this time point. Thus,
this mutation-specific K12 siRNA appears to be highly specific.
Since primary epithelial cell cultures from affected patients were
not available, a tissue culture model for the dominant-negative
MECD disorder was established by co-transfecting PtK2 cells with
a mixture of mutant and wild type K12 expression constructs
along with wild type K3 expression construct. Similarly, cells co-
transfected with wild-type K12-EGFP and K3 constructs were
used as a model of normal corneal epithelia. The ability of lead
siRNA inhibitor K12-L132P-9 to selectively block mutant K12
expression was assayed by counting the percentage of cells in
which keratin filaments were in filamentous form or in aggregate
form at 48 hours post-transfection in a blinded experiment. Cells
transfected with wild type K12-EGFP construct predominantly
formed normal keratin filaments (92.5%) with little evidence of
aggregate formation (5%). In contrast, cells transfected with the
mutant K12-EGFP construct contained a much higher percentage
of keratin aggregates (41.75%; p,0.001), as shown in Fig. 7A–D.
As expected for a dominant-negative mechanism, cells transfected
with a mixture of wild-type and mutant (1:1 molar ratio) K12
expression plasmids with wild-type K3 expression plasmids
Figure 4. A comprehensive siRNA sequence walk for the K12 mutation Leu132Pro. This sequence walk shows the best siRNA was at
position 9 (K12-L132P-9) which was very potent against the mutant reporter (pink line on plots) even at as low as 10 pM but did not significantly
inhibit wild-type (blue line on plots) at concentrations as high as 6.25 nM. siRNA inhibitor K12-L132P-13 did not affect wild-type or mutant reporter
while K12-L132P-2 and K12-L132P-3 knocked down both alleles to varying degrees NSC4 is a non-specific control siRNA, (negative control). siLUC is
an siRNA specific for luciferase (positive control).
doi:10.1371/journal.pone.0028582.g004
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were defective in keratin filament formation (only 61.5% of the
cells contained predominantly keratin filaments; p,0.001; Fig. 7E).
Co-transfection of cells with a mixture of wild-type K12 and K3,
and mutant K12, expression plasmids along with siRNA K12-
L132P-9 significantly rescued the ability to form keratin filaments
(74.75% of the cells contained normal keratin filaments; p,0.001;
Fig. 7E).
Discussion
In the dominantly inherited genetic disorders, where the
pathomechanism is that of dominant-negative interference rather
than loss-of-function/haploinsufficiency, therapeutic approaches
such as gene replacement therapy are not appropriate and instead,
a means of silencing mutant alleles would be a possible route to
therapy [19,20]. Over the years, a number of gene silencing
methods have emerged, such as antisense RNA, morpholino
oligonucleotides, or peptide nucleic acids, which can block
translation of a target mRNA species of choice [10]. Unfortu-
nately, because they are largely based on irreversible binding of
the target mRNA by the antisense molecule, these systems are
poorly discriminating for alleles that differ by only a few
nucleotides or as the case is here, a single nucleotide. In recent
years the use of synthetic siRNA, which exploit the naturally
occurring RNAi pathway present within all human cells, has
become a popular choice for development of therapy based on
gene silencing [9,21]. Within the cell, siRNA enters and forms the
Figure 5. Differential inhibition of mutant K12 versus wild type by allele-specific siRNAs in cultured cells. (A) AD293 cells were
transfected with wild-type or mutant K12-EGFP construct and siRNAs K12-L132P-9, 14 and 15 at a final concentration of 5 nM. Fluorescent imaging at
48 hours post-transfection showed that the expression of both wild type and mutant K12-EGFP constructs was almost equally strong for the cells
treated with NSC4 while there was a significant reduction of fluorescence in the cells transfected with mutant K12-EGFP and inhibitors, although a
subtle reduction of fluorescence in the cells treated with K12-L132P-9 or 15 was also observed. Original magnification 106(except bright field image,
406). Scale bar=50 mm. (B) To confirm and quantify the highly differential inhibitory effect of K12-L132P-9 on mutant K12, western blot analysis was
performed. AD293 cells were transiently co-transfected with either K12-L132P-EGFP expression construct and siRNA NSC4 (a non-specific control), or
K12-L132P-9 at a final concentration of 5 nM. When cells were treated with K12-L132P-9, the mutant K12-EGFP was almost completely knocked
down, while expression of wild type K12 construct treated with the same siRNA showed a negligible reduction compared with NSC4 treatment.
Wt=wild type and mut=mutant.
doi:10.1371/journal.pone.0028582.g005
Figure 6. Lack of off-target silencing of other keratins by lead
inhibitor for K12 Leu132Pro mutation, siRNA K12-L132P-9.
SimplyBlue staining of cytoskeletal protein extracts from HaCaT cells
revealed allele specific K12-L132P-9 siRNA had negligable effect on the
range of endogenous keratins expressed in the HaCaT cell line. In
contrast, a positive control siRNA directed against wild-type K6a
demonstrated a dramatic decrease in K6a expression. Non-specific
control siRNA NSC4 had no effect on keratin protein expression profile.
doi:10.1371/journal.pone.0028582.g006
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– a highly processive RNA-protein catalytic complex which
functions by selecting and degrading target mRNA species [22].
siRNAs are typically 13 kDa, double-stranded 19-mer RNA
molecules, flanked by single stranded 2-nucleotide overhangs
[23] and are therefore much closer in size to a small molecule drug
(typically ,550 Da) rather than a gene therapy vector (typically 5–
10 MDa). This has obvious advantages for delivery and currently,
international efforts are on-going in both industry and academia to
develop a non-invasive delivery vehicle for siRNA for skin [20]
and cornea [24].
A major challenge to development of therapeutics aimed at
silencing mutant alleles is the requirement for a high-degree of
sequence specificity. In MECD and most of the other keratin
disorders, the majority of causative mutations are point mutations
[4,25]. Remarkably, it has proven possible to develop potent,
highly efficacious siRNA molecules that can discriminate a single
nucleotide [21,26,27]. Here, we have adapted the recently
reported fluorescent protein sequence walk methodology [27], to
employ a luciferase co-reporter system. This allows for a higher
throughput 96-well format assay, as well as internal normalization
to control for cell viability and/or transfection efficiency. A
standardized range of siRNA concentrations from 6.25 nM down
to 10 pM, was used to measure potency, as well as sequence
specificity. Some of the allele-specific inhibitors identified were
highly potent with a high degree of single-nucleotide specificity, for
example, siRNA K12-L132P-9 (Fig. 4), had a half maximal
inhibitory concentration (IC50) of about 10 pM, which is better
than many small molecule drugs in clinical practice. Remarkably,
the best lead inhibitors developed here are capable of severely
knocking down mutant keratin protein expression (Fig. 5), without
any obvious off-target effects on other keratin proteins (Fig. 6) as
well as reversing cytoskeletal dysfunction in a cell culture model
system (Fig. 7). The inhibitors, which performed well in all three
assays, are suitable for further preclinical development such as
GMP manufacture and toxicology, to pave the way for future
clinical applications.
Knock down of K12 mutant allele subsequent to application of
allele specific siRNA therapy requires single copy expression of
K12 to be sufficient for normal corneal epithelial function.
Previous studies using gene targeted animal models, in which one
allele of the murine K12 gene (Krt1-12) was ablated, show no
corneal fragility phenotype [28]. Similarly, human subjects
heterozygous for a K14 null mutation show no skin fragility
phenotype [29]. These findings demonstrate there is no haploin-
sufficiency issue with certain type I keratin genes, including K12
and K14 and therefore one allele is sufficient to allow normal
epithelial function, validating the mutation-specific siRNA ap-
proach taken here.
Although MECD is genetically heterogeneous, there are a
number of recurrent mutations, including a common European
founder mutation [3,12], that are suitable for allele-specific
approaches such as that taken here. Other types of corneal
dystrophies arise from mutations in the transforming growth factor
beta-induced gene (TGFBI, also known as BIGH3) on chromo-
some 5q31 [30,31,32]. The underlying pathology of both keratin
and BIGH3 corneal dystrophies is very similar – both are
predominantly caused by dominant-negative missense mutations.
Thus, while MECD is ideal for therapy development and
optimization, in the clinic BIGH3 may well be a major target,
in addition to K3 and K12. A disadvantage of the BIGH3
dystrophies for siRNA development is that the extracellular
aggregates found in these disorders take years or decades to
develop clinically, making assays of efficacy difficult to model in
cultured cells or animal models. The high turnover of the anterior
epithelium in 5–7 days [33] coupled with the rapid appearance/
disappearance of the intracellular mutant keratin aggregates in
MECD combine to make this an ideal model corneal dystrophy
for siRNA therapy. Lessons learned in development of specific
inhibitors and their delivery to the cornea in MECD can then be
rapidly translated to the more common and more clinically severe
BIGH3 disorders.
The biggest hurdle to clinical application of these siRNAs is that
of finding an efficacious and non-invasive delivery system. The
cornea provides a highly attractive target tissue for siRNA therapy
both in terms of optimization of delivery strategies and as a target
tissue for corneal disease. As a target tissue, the corneal epithelium
is a thin, four cell layer non-cornified stratified epithelium, and
with no equivalent of the skin barrier layers to penetrate, delivery
is easier than in epidermal field, where there is also a great deal of
activity in siRNA therapy development. The cornea is therefore
ideal as a proof-of-concept tool for translation of siRNA therapy
into clinical practice as it is so easily accessible, disease status is
easily monitored and the surface to be treated is small. Here we
have demonstrated that it is possible to make highly potent and
mutation-specific siRNA therapy reagents that target MECD-
causing K12 mutations. Here, we chose the Leu132Pro mutation
associated with a severe MECD phenotype, as there is great
clinical need in the affected family. Similar siRNAs are in
development for the other MECD associated mutations, including
the more common Arg135Thr mutation.
The next step toward clinical application requires assessment of
siRNA in vivo using knock-in reporter gene and phenotypic disease
Figure 7. Therapeutic siRNA significantly reduces aggregate
formation. Ptk2 cells were co-transfected with K3 and wild type K12-
EGFP or mutant K12-EGFP or a 1:1 ratio of both wild type and mutated
K12-EGFP plasmids along with wild type K3 and mutant specific siRNAs
and incubated for 72 hours. Filamentous keratin was visualized by
direct fluorescence of EGFP-tagged K12. There was a significant
difference in aggregate formation between cells treated with siRNA
K12-L132P-9 and those treated with NSC4; p,0.001. Figure 7D is
representative of a cell with correct filament formation while Figures 7B
and 7D illustrate the formation of keratin aggregates. Within the graph,
black=filament formation; light grey=occurrence of both filaments
and aggregates; and dark grey=aggregates. Original magnification
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for the mutant allele at higher doses required for in vivo delivery
ensuring significant suppression of the wild-type allele does not
ensue, alongside studies of frequency and concentration of dosage
requirements will greatly inform advances into clinical trials. The
highly processive nature of RISC combined with the very potent
nature of the Leu132Pro siRNA described here, should allow a
relatively low dose of siRNA to be delivered to the cell. Coupled
with a suitable delivery mechanism, be that chemical modification
of the siRNA itself, formulations or enhancers to give optimal cell
entry or physical methods to increase cell uptake, these small




An extended British family with MECD was studied where the
clinical presentation was consistently severe. All individuals were
examined using a slit lamp by an experienced ophthalmologist.
EDTA blood samples were obtained from the patients with written
informed consent and Institutional Ethics Committee approval
was obtained that complied with the Declaration of Helsinki
Principles (Tayside Committee on Medical Research Ethics A,
study number 249/95). DNA was extracted following standard
procedures. Molecular genetic analysis of keratin genes KRT3 and
KRT12 was performed as previously described by Irvine et al 1997
[3].
Expression constructs
Total human corneal epithelial mRNA was extracted from
human corneal tissue using the QuickPrep micro mRNA
purification kit (Amersham Biosciences UK Ltd., Bucks, UK).
The full length K12 cDNA, including 39UTR but excluding the
poly-A signal was obtained by PCR using the following primers:
K12M1F 59-CCT TCC CCA GGC CAT GGA TCT and
K12M1R2 59-CAA TTA ACT CTA TTA AAA CAA. The full-
length human K3 coding sequence was amplified using primer
pair K3F1 59-CTT CGC CAA GCT CCT TAC C and K3R1 59-
CGA TGC TGA TGC GTG CTC T. PCR fragments were
cloned into pCR2.1 (Invitrogen, Paisley, UK) and fully sequenced.
To allow EGFP (enhanced green fluorescent protein) tagging, the
termination codons of the wild-type and Leu132Pro mutant K12
cDNAs were eliminated using QuickChange
TM Site-Directed
Mutagenesis (Stratagene; Agilent Technologies, Cheshire, UK)
using primers 59-ATT GAA GAA CTA ATG GGA AAT TTC
ACA AGA TC and 59-GAT CTT GTG AAA TTT CCC ATT
AGT TCT TCA AT. To generate EGFP expression constructs,
EcoR I–Bgl II fragments were subcloned into vector pEGFP-N3
(Clontech, France) EcoR I and BamH I. These constructs were
designated as K12-EGFP and K12Leu132Pro-EGFP. The
unmodified K3 cDNA was subcloned into pcDNA3 for mamma-
lian expression (using EcoR I).
K12-Luc reporter constructs
Mutations Leu132Pro and Arg135Thr were introduced into the
K12 cDNA clone (in pCR2.1) with the QuickChange
TM Site-
Directed Mutagenesis (Stratagene; Agilent Technologies, Che-
shire, UK), using primer pairs 59-ACT ATG CAA AAT CCT
AAT GAT AGA TTA and 59-TAA TCT ATC ATT AGG ATT
TTG CAT AGT (for Leu132Pro), and 59-AAT CTT AAT GAT
ACA TTA GCT TCC TAC and 59-GTA GGA AGC TAA TGT
ATC ATT AAG ATT (for Arg135Thr). To generate luciferase
reporter constructs for siRNA screening, wild-type and mutant
K12 cDNA fragments were subcloned into psiTEST-LUC-target
vector (York Bioscience Ltd, York, UK) using Not I and BamH I. A
Renilla luciferase expression construct (pRL-CMV, Promega,
Southampton, UK) was used as an internal control for both cell
viability and transfection efficiency.
siRNA design
siRNAs (19+2 format; 19-nucleotide duplex with two 39 uracyl
nucleotide overhangs) were synthesized by MWG Biotech AG
(Ebersberg, Germany) to screen all possible target sequences
containing the Leu132Pro mutation, plus positive and negative
controls. This T.C point mutation occurs at position 395 in the
K12 coding sequence, numbering by convention where the
initiating ATG, =1 and excluding the 59UTR (c.395T.C). The
sense and antisense strands for the mutation-specific siRNA
reagent designated as K12-L132P-1 were 59-AGA AAC UAU
GCA AAA UCC UU and 59-GGA UUU UGC AUA GUU UCU
UU, respectively (mutant position underlined). siRNAs K12-
L132P-2 through K12-L132P-19 were designed similarly and the
sense strands are represented in Table S1. The sense and antisense
strands for positive control siRNA (siLuc) targeting the firefly
luciferase gene were 59-GUG CGU UGC UAG UAC CAA CUU
and 59-GUU GGU ACU AGC AAC GCA CUU, respectively.
The sense and antisense sequences for the non-specific control
siRNA (NSC4; an inverted bacterial b-galactosidase sequence)
were 59-UAG CGA CUA AAC ACA UCA AUU and 59-UUG
AUG UGU UUA GUC GCU AUU, respectively.
Cell culture
Human AD293 embryonic kidney cells (Invitrogen, Paisley,
UK) and Potorous tridactylis (rat kangaroo) kidney cell line PtK2 [34]
were maintained in DMEM (Invitrogen, Paisley, UK) containing
4.5 g/L glucose and 10% fetal calf serum (FCS; Invitrogen,
Paisley, UK), supplemented with 2 mM L-glutamine and 1 mM
sodium pyruvate. Cells were incubated at 37uC with 5% CO2
supplement and passaged following standard laboratory proce-
dures.
Luciferase Reporter Assay
AD293 cells were cells of choice for the luciferase assay as they
do not express endogenous K12 or K12 and therefore we can
control what is expressed. Cells were plated at 7610
3 cells/well in
a 96-well plate, resulting in 80% cell confluence at the time of
transfection. Cells were transfected in quadruplicate with a
mixture of 15 ng firefly luciferase expression plasmid, 1 ng Renilla
luciferase expression plasmid and siRNA (final concentration
0.01–6.25 nM per transfection) which was diluted to 25 mli n
optiMEM medium (Invitrogen, Paisley, UK). 1 mg Lipofectamine
2000 (Invitrogen, Paisley, UK) was incubated in optiMEM
medium at room temperature for 5 minutes. This mixture was
added to the nucleic acids and incubated for 20 minutes at room
temperature, before addition to cells. The Dual-Luciferase
Reporter Assay (Promega, Southampton, UK) was used to
measure the effect of siRNA on luciferase expression 24 hours
after transfection. The assay was used according to manufacturer’s
instructions. Briefly, the medium was removed and cells were
washed with PBS before replacement with Passive Lysis Buffer
(Promega, Southampton, UK). Cells were shaken on a plate
shaker for 15 minutes to ensure cells were fully lysed, before the
activities of both Firefly and Renilla luciferase were measured
sequentially using the LUMIstar OPTIMA (BMG Labtech,
Aylesbury, UK).
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Cells were incubated for 48 hours after transfection, then
washed with PBS and lysed with NuPAGE 16 loading and
solubilization buffer (Invitrogen, Paisley, UK). The extracted
protein samples were denatured at 100uC for 5 minutes before
being resolved on a 4–12% NuPAGE gel with SDS-MOPS
running buffer (Invitrogen, Paisley, UK). To ensure adequate
protein transfer and equal loading of samples the membrane was
stained with Ponceau S (Sigma, Poole, UK) before immunoblot-
ting. The K12 fusion protein tagged with EGFP (K12wt-EGFP
and K12Leu132Pro-EGFP) was stained with anti-EGFP antibody
(diluted 1:1000; Roche, West Sussex, UK) for 1 hour at room
temperature and anti-ß-actin antibody (diluted 1:5000; Sigma,
Poole, UK) was used as an endogenous control. Membranes were
washed with TBS-Tween for 10 minutes three times before being
stained with anti-mouse HRP secondary antibody (diluted 1:1000;
Dakocytomation, Cambridge, UK) for 1 hour at room tempera-
ture. After another three 10 minute washes with TBS-Tween, the
membrane was treated with the mixture of ECL solution I and II
(1:1) for 2 minutes and X-ray film exposures were developed.
Transient transfections of HaCaT cells
The lead inhibitor for K12 Leu132Pro mutation was investi-
gated for off-target effects on other keratins in HaCaT cells; known
to express a wide range of keratins. HaCaT cells were left
untreated or incubated with the lead inhibitor for K12 Leu132Pro
(K12-L132P-9), or a positive control siRNA against the 39UTR
region of K6a or a non-specific control siRNA (NSC4).
Transfections were set up in duplicate in 12 well plates using
Lipofectamine RNAiMax (Invitrogen, Paisley, UK) according to
manufacturer’s instructions for the ‘reverse transfection’ protocol.
Briefly, 2 ml siRNA (5 mM) was diluted in 200 ml Opti-MEM
medium, 2 ml Lipofectamine RNAiMax was added, mixed and
incubated at room temperature for 20 minutes. 200 ml siRNA/
Lipofectamine RNAiMax complexes were added to each well.
Trypsinized HaCaT cells (8610
4 cells in 1.8 ml DMEM, 10%
fetal bovine serum) were added to each well to give a final siRNA
concentration of 5 nM. Cells were incubated at 37uC for 72 hours
before cells were harvested for insoluble cytoskeletal protein
extraction.
Cytoskeletal extractions
Cytoskeletal extracts were made 72 hours post-transfection
using a low salt, high salt buffer system as previously described
[35]. Cytoskeletal protein samples were heated in the presence of
reducing agent to 70uC for 10 minutes and resolved on 4–12%
NuPage Bis Tris gels (Invitrogen) with SDS-MOPS running buffer
(Invitrogen, Paisley, UK). A See Blue Prestained protein standard
(Invitrogen) was used to allow accurate determination of protein
size. Gels were stained with SimplyBlue SafeStain (Invitrogen) and
each lane examined for the presence of cytokeratins based on
known molecular weight.
Keratin aggregation assay
Ptk2 cells were chosen for this assay as their flat morphology
allows for easier imaging of aggregate or filament formation. Cells
were plated at 1610
5 cells per well in a 24 well plate, each well
contained a sterile 13 mm diameter cover-slip and cells were co-
transfected in quadruplicate with wild-type, mutant, or a 1:1
mixture of wild-type and mutant K12 expression plasmids along
with a wild-type K3 expression construct (400 ng DNA per
transfection in total) in 1 mg Lipofectamine 2000 and optiMEM
medium (Invitrogen, Paisley, UK). In siRNA experiments, siRNA
was co-transfected at a final concentration of 5 nM. Cells were
incubated for 72 hours with a change of medium at 24 hours.
After 72 hours, cells were fixed with 3% paraformaldehyde for
20 minutes. The keratin cytoskeleton was visualized either by
immunoflurorescence staining (K3 antibody AE5; Abcam, Cam-
bridge, UK) or directly via EGFP. Nuclei were counterstained
with 49,6-diamidino-2-phenylindole before being mounted onto
slides with hydramount medium. At least 100 cells per coverslip
were analyzed for the presence of filaments only, aggregates only
or both filaments and aggregates. Statistical analysis was
performed on aggregate cell counts using a one-way analysis of
variance (ANOVA) with a p,0.05 considered significant.
Statistical analysis was performed with the use of SPSS version 17.
Supporting Information
Figure S1 Figure demonstrates the pedigree of MECD
family 1. The arrow denotes the proband.
(TIF)
Table S1 siRNA sequence walk against K12 mutation
Leu132Pro (DNA mutation c.395T.C). Bold denotes
mutated nucleotide. The sequences of a non-specific control
siRNA (NSC4) and a positive control against firefly luciferase
(siLuc) are also shown.
(DOC)
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